Science Corporation has recently acquired the IP and related assets of the Pixium Vision Prima implant, a groundbreaking technology that offers a potential solution for individuals suffering from blindness. The Prima System, which acts as a photovoltaic substitute for photoreceptors, has already received FDA breakthrough device designation and provides simultaneous use of central prosthetic and peripheral natural vision. It was specifically designed for patients with atrophic dry age-related macular degeneration (AMD), offering a miniaturized, wireless, subretinal implant paired with a pocket computer and glasses.
With this acquisition, Neuralink co-founder Max Hodak, who founded Science Corporation, expressed excitement about the opportunity it presents for developing brain-computer interface (BCI) technology for vision restoration. The acquisition also ensures continuity for patients enrolled in Pixium Vision’s clinical trials, as Science is now able to provide a future for the program and further advance innovative products using different modalities.
Pixium Vision had been seeking a potential buyer for its technology, and with Science stepping in to acquire the Prima implant technology, there is a sense of relief among company leadership. Outgoing Pixium CEO Lloyd Diamond expressed confidence in Science’s ability to continue the development and commercialization of the Prima System, stating that it now has a home with a team dedicated to helping patients.
The acquisition of the Prima System adds to Science’s already impressive IP portfolio and represents a significant step forward in the company’s mission to develop cutting-edge BCI technology. The deal was finalized after Pixium went into liquidation but has been approved by the Paris Commercial Court. While the terms of the acquisition were not disclosed, both companies are looking forward to the potential impact of this collaboration on the field of vision restoration and the lives of individuals affected by blindness.